Literature DB >> 14596629

Methods to analyse cost data of patients who withdraw in a clinical trial setting.

Jan B Oostenbrink1, Maiwenn J Al, Maureen P M H Rutten-van Mölken.   

Abstract

BACKGROUND: Missing data resulting from premature study withdrawal are a common problem in the analysis of longitudinal data in clinical trials. To date, this subject has received little attention in the context of economic evaluations and with regard to the analysis of cost data.
OBJECTIVES: To (i) demonstrate the impact of patients who drop out during the study on the outcomes of an economic evaluation, and (ii) to compare the mean and variation in costs after applying five different methods to deal with incomplete data: multiple imputation, complete cases analysis, linear extrapolation, predicted mean and hot decking. STUDY
DESIGN: The study was performed using cost data collected in two randomised clinical trials comparing patients with chronic obstructive pulmonary disease receiving either tiotropium bromide or ipratropium bromide. The overall dropout rate was 17%, with the daily costs of the dropouts approximately 4 times higher than the costs of the completers.
METHODS: Multiple imputation is a principled method that deals with missing observations by replacing each missing observation with a set of multiple plausible values. The variance between the resulting multiple datasets is combined with the variance between the datasets to take account of the extra uncertainty that results from missing data. The outcomes after multiple imputation were compared with the results of four naive methods to deal with missing observations: complete cases analysis, linear extrapolation, predicted mean and hot decking. All costs were expressed in 2001 euros.
RESULTS: In the tiotropium bromide group, mean (standard error) costs varied from Euro 955 (137) after complete cases analysis to Euro 1298 (198) after linear extrapolation. The corresponding estimates in the ipratropium bromide group were Euro 970 (125) and Euro 1561 (244), respectively. The difference in costs between treatment groups varied from -Euro 15 (95% CI: -379 to 349) after complete cases analysis to -Euro 402 (95% CI: -883 to 79) after predicted mean, in favour of the tiotropium bromide group. The difference in costs according to the other methods varied from -Euro 263 (95% CI: -878 to 353) after linear extrapolation to -Euro 265 (95% CI: -709 to 180) after multiple imputation to -Euro 359 (95% CI: -771 to 54) after hot decking.
CONCLUSION: This study showed that the method of dealing with the data of the dropouts had a large impact on the outcomes of an economic evaluation. Information about the rate of patient withdrawal and the way data of dropouts are treated is of vital importance in assessing the results of economic evaluations and should always be reported. Multiple imputation is a principled method that can be used to deal with the data of these patients.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14596629     DOI: 10.2165/00019053-200321150-00004

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  9 in total

Review 1.  Multiple imputation in health-care databases: an overview and some applications.

Authors:  D B Rubin; N Schenker
Journal:  Stat Med       Date:  1991-04       Impact factor: 2.373

2.  The St George's Respiratory Questionnaire.

Authors:  P W Jones; F H Quirk; C M Baveystock
Journal:  Respir Med       Date:  1991-09       Impact factor: 3.415

Review 3.  Analysis and interpretation of cost data in randomised controlled trials: review of published studies.

Authors:  J A Barber; S G Thompson
Journal:  BMJ       Date:  1998-10-31

4.  Estimating medical costs from incomplete follow-up data.

Authors:  D Y Lin; E J Feuer; R Etzioni; Y Wax
Journal:  Biometrics       Date:  1997-06       Impact factor: 2.571

5.  Longitudinal data analysis for discrete and continuous outcomes.

Authors:  S L Zeger; K Y Liang
Journal:  Biometrics       Date:  1986-03       Impact factor: 2.571

Review 6.  Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary.

Authors:  R A Pauwels; A S Buist; P M Calverley; C R Jenkins; S S Hurd
Journal:  Am J Respir Crit Care Med       Date:  2001-04       Impact factor: 21.405

7.  Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium.

Authors:  W Vincken; J A van Noord; A P M Greefhorst; Th A Bantje; S Kesten; L Korducki; P J G Cornelissen
Journal:  Eur Respir J       Date:  2002-02       Impact factor: 16.671

8.  Statistical analysis of cost outcomes in a randomized controlled clinical trial.

Authors:  M P Rutten-van Mölken; E K van Doorslaer; R C van Vliet
Journal:  Health Econ       Date:  1994 Sep-Oct       Impact factor: 3.046

9.  A multiple imputation strategy for clinical trials with truncation of patient data.

Authors:  P W Lavori; R Dawson; D Shera
Journal:  Stat Med       Date:  1995-09-15       Impact factor: 2.373

  9 in total
  26 in total

Review 1.  Assessment of progression of COPD: report of a workshop held in Leuven, 11-12 March 2004.

Authors:  M Decramer; R Gosselink; M Rutten-Van Mölken; J Buffels; O Van Schayck; P-A Gevenois; R Pellegrino; E Derom; W De Backer
Journal:  Thorax       Date:  2005-04       Impact factor: 9.139

Review 2.  Economic evaluations: a new avenue of outcome assessment in spinal disorders.

Authors:  Nicole van der Roer; Norbert Boos; Maurits W van Tulder
Journal:  Eur Spine J       Date:  2005-12-01       Impact factor: 3.134

3.  Economic evaluation of dose-response resistance training in older women: a cost-effectiveness and cost-utility analysis.

Authors:  J C Davis; C A Marra; M C Robertson; K M Khan; M Najafzadeh; M C Ashe; T Liu-Ambrose
Journal:  Osteoporos Int       Date:  2010-08-04       Impact factor: 4.507

4.  Estimating mean total costs in the presence of censoring: a comparative assessment of methods.

Authors:  Tracey A Young
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

5.  Sustained economic benefits of resistance training in community-dwelling senior women.

Authors:  Jennifer C Davis; Carlo A Marra; M Clare Robertson; Mehdi Najafzadeh; Teresa Liu-Ambrose
Journal:  J Am Geriatr Soc       Date:  2011-06-30       Impact factor: 5.562

6.  A method to estimate off-schedule observations in a longitudinal study.

Authors:  Katherine W Reeves; Roslyn A Stone; Francesmary Modugno; Roberta B Ness; Victor G Vogel; Joel L Weissfeld; Laurel A Habel; Marike Vuga; Jane A Cauley
Journal:  Ann Epidemiol       Date:  2011-04       Impact factor: 3.797

7.  Collaborative stepped care for anxiety disorders in primary care: aims and design of a randomized controlled trial.

Authors:  Anna D T Muntingh; Christina M van der Feltz-Cornelis; Harm W J van Marwijk; Philip Spinhoven; Willem J J Assendelft; Margot W M de Waal; Leona Hakkaart-van Roijen; Herman J Adèr; Anton J L M van Balkom
Journal:  BMC Health Serv Res       Date:  2009-09-08       Impact factor: 2.655

8.  Societal costs and quality of life of children suffering from attention deficient hyperactivity disorder (ADHD).

Authors:  L Hakkaart-van Roijen; B W C Zwirs; C Bouwmans; S S Tan; T W J Schulpen; L Vlasveld; J K Buitelaar
Journal:  Eur Child Adolesc Psychiatry       Date:  2007-05-04       Impact factor: 4.785

9.  Challenges with cost-utility analyses of behavioural interventions among older adults at risk for dementia.

Authors:  Jennifer C Davis; Stirling Bryan; Carlo A Marra; Ging-Yuek R Hsiung; Teresa Liu-Ambrose
Journal:  Br J Sports Med       Date:  2013-11-06       Impact factor: 13.800

10.  Cost-effectiveness analysis of cognitive behaviour therapy for treatment of minor or mild-major depression in elderly patients with type 2 diabetes: study protocol for the economic evaluation alongside the MIND-DIA randomized controlled trial (MIND-DIA CEA).

Authors:  Nadja Chernyak; Frank Petrak; Kristin Plack; Martin Hautzinger; Matthias J Müller; Guido Giani; Andrea Icks
Journal:  BMC Geriatr       Date:  2009-07-01       Impact factor: 3.921

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.